BETA BIONICS INC (BBNX) Stock Overview
USA - NASDAQ:BBNX - US08659B1026 - Common Stock
BBNX Key Statistics, Chart & Performance
The current stock price of BBNX is 24.28 USD. In the past month the price increased by 19.62%.
BBNX Latest News, Press Relases and Analysis
BBNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.37 | 220.36B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.34 | 195.51B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.23 | 149.61B | ||
| SYK | STRYKER CORP | 29.26 | 143.72B | ||
| MDT | MEDTRONIC PLC | 16.86 | 119.59B | ||
| BDX | BECTON DICKINSON AND CO | 12.91 | 52.80B | ||
| IDXX | IDEXX LABORATORIES INC | 52.82 | 50.75B | ||
| EW | EDWARDS LIFESCIENCES CORP | 31.98 | 48.25B | ||
| RMD | RESMED INC | 26.87 | 37.44B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.04 | 36.25B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.25 | 26.29B | ||
| DXCM | DEXCOM INC | 40.72 | 27.15B |
Related stock screener links
About BBNX
Company Profile
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 291 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
Company Info
BETA BIONICS INC
11 Hughes
Irvine CALIFORNIA US
Employees: 291
Phone: 19494277785
BETA BIONICS INC / BBNX FAQ
What does BBNX do?
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 291 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
Can you provide the latest stock price for BETA BIONICS INC?
The current stock price of BBNX is 24.28 USD. The price increased by 2.23% in the last trading session.
Does BBNX stock pay dividends?
BBNX does not pay a dividend.
How is the ChartMill rating for BETA BIONICS INC?
BBNX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for BBNX stock?
The Revenue of BETA BIONICS INC (BBNX) is expected to grow by 40.77% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for BBNX stock?
BETA BIONICS INC (BBNX) will report earnings on 2025-10-28, after the market close.
Can you provide the ownership details for BBNX stock?
You can find the ownership structure of BETA BIONICS INC (BBNX) on the Ownership tab.
BBNX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to BBNX.
BBNX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BBNX. BBNX has a great financial health rating, but its profitability evaluates not so good.
BBNX Financial Highlights
Over the last trailing twelve months BBNX reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -24.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.59% | ||
| ROE | -18.15% | ||
| Debt/Equity | 0 |
BBNX Forecast & Estimates
15 analysts have analysed BBNX and the average price target is 24.14 USD. This implies a price decrease of -0.58% is expected in the next year compared to the current price of 24.28.
For the next year, analysts expect an EPS growth of -1.65% and a revenue growth 40.77% for BBNX